{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:08:52Z","timestamp":1787504932043,"version":"build-2736575974"},"reference-count":130,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020908","name":"Pfizer France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.dld.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T20:14:10Z","timestamp":1712434450000},"page":"1270-1280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus"],"prefix":"10.1016","volume":"56","author":[{"given":"Pablo A.","family":"Olivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-054X","authenticated-orcid":false,"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C.","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Peretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-6691","authenticated-orcid":false,"given":"Paulo G.","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Rocha","family":"Faria-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.03.010_bib0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Peyrin-Biroulet L. Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.03.010_bib0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.03.010_bib0003","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0004","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.03.010_bib0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0006","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105592","article-title":"Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases","volume":"90","author":"Avouac","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.dld.2024.03.010_bib0009","unstructured":"U.S. Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) n.d. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (accessed October 9, 2020)."},{"key":"10.1016\/j.dld.2024.03.010_bib0010","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions n.d. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death?utm_medium=email&utm_source=govdelivery (accessed November 10, 2022)."},{"key":"10.1016\/j.dld.2024.03.010_bib0011","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki (accessed December 11, 2022)."},{"key":"10.1016\/j.dld.2024.03.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis","author":"Lasa","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.dld.2024.03.010_bib0013","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.3748\/wjg.v28.i26.3092","article-title":"Shared decision-making in the management of patients with inflammatory bowel disease","volume":"28","author":"Song","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2024.03.010_bib0014","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gutjnl-2011-300988","article-title":"Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options","volume":"61","author":"Siegel","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.03.010_bib0015","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence n.d. https:\/\/www.cebm.net\/wp-content\/uploads\/2014\/06\/CEBM-Levels-of-Evidence-2.1.pdf (accessed May 26, 2023)."},{"key":"10.1016\/j.dld.2024.03.010_bib0016","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dld.2024.03.010_bib0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.dld.2024.03.010_bib0018","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase iii and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.dld.2024.03.010_bib0019","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.dld.2024.03.010_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236894","article-title":"The effect of upadacitinib on lipid profile and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"11","author":"Makris","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0023","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","article-title":"PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD","volume":"14","author":"Gilardi","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0024","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/cpdd.957","article-title":"Effect of upadacitinib on the pharmacokinetics of rosuvastatin or atorvastatin in healthy subjects","volume":"10","author":"Mohamed","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dld.2024.03.010_bib0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cpdd.1015","article-title":"Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants","volume":"11","author":"Anderson","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dld.2024.03.010_bib0026","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/apt.17509","article-title":"Review article: risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs","author":"Olivera","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.03.010_bib0028","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0029","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","article-title":"Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the ibm marketscan\u00ae administrative claims database with tofacitinib trial data","volume":"27","author":"Curtis","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0030","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.dld.2024.03.010_bib0031","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0032","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.dld.2024.03.010_bib0033","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.03.010_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19895492","article-title":"Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Xie","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0035","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0036","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.03.010_bib0037","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","article-title":"Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis","volume":"52","author":"Lair-Mehiri","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0038","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10620-019-05492-y","article-title":"Real-world experience with tofacitinib in IBD at a tertiary center","volume":"64","author":"Weisshof","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2024.03.010_bib0039","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0040","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0041","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5217\/ir.2020.00030","article-title":"Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis","volume":"19","author":"Shimizu","year":"2021","journal-title":"Intest Res"},{"key":"10.1016\/j.dld.2024.03.010_bib0042","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry","author":"Straatmijer","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.03.010_bib0043","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.cgh.2020.10.025","article-title":"Real-world effectiveness and safety of tofacitinib in crohn's disease and IBD-U: a multicenter study from the TROPIC consortium","volume":"19","author":"Fenster","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0044","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and Anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2024.03.010_bib0045","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2022.37.e123","article-title":"The comparative risk of serious adverse events with tofacitinib and TNF inhibitors in patients with ulcerative colitis: the korean experience as revealed by a national database","volume":"37","author":"Seo","year":"2022","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.dld.2024.03.010_bib0046","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0047","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","article-title":"JAK inhibition in inflammatory bowel disease","volume":"13","author":"Olivera","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.dld.2024.03.010_bib0048","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0049","unstructured":"Sedano R., Ma C., Jairath V., Feagan B.G. Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease. vol. 18. 2022."},{"key":"10.1016\/j.dld.2024.03.010_bib0050","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.dld.2024.03.010_bib0051","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.03.010_bib0052","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2020.1780120","article-title":"JAK selectivity: more precision less troubles","volume":"14","author":"Roda","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0053","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/j.gastro.2022.09.011","article-title":"Is selectivity the JAKpot winner for inflammatory bowel disease treatment?","volume":"163","author":"D'Amico","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.03.010_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.dld.2024.03.010_bib0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0056","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0057","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0058","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.03.010_bib0059","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.03.010_bib0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.03.010_bib0061","first-page":"1","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"6736","author":"Vermeire","year":"2016","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.dld.2024.03.010_bib0062","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad104","article-title":"Major adverse cardiovascular events by baseline cardiovascular risk in patients with ulcerative colitis treated with tofacitinib: data from the OCTAVE clinical programme","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0063","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.dld.2024.03.010_bib0064","first-page":"E1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2024.03.010_bib0065","first-page":"II2","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2024.03.010_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.dld.2024.03.010_bib0067","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/09612033221147471","article-title":"Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis","volume":"32","author":"Bello","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.dld.2024.03.010_bib0068","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","article-title":"Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies","volume":"8","author":"Fumery","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0069","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ecco-jcc\/jjy164","article-title":"Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals","volume":"13","author":"Aarestrup","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0070","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1097\/MIB.0000000000000109","article-title":"Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease","volume":"20","author":"Aggarwal","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0071","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0072","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrgastro.2014.202","article-title":"Epidemiology, risk factors and management of cardiovascular diseases in IBD","volume":"12","author":"Singh","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/annotation\/b4a49855-87b9-436a-a4bd-bc64b50a6c93","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death - a danish nationwide cohort study","volume":"8","author":"Kristensen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2024.03.010_bib0074","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.03.010_bib0075","first-page":"1","article-title":"Disease activity in inflammatory bowel disease is associated with arterial vascular disease","volume":"XX","author":"Card","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0201991","article-title":"Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease","volume":"13","author":"Le Gall","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2024.03.010_bib0077","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.14309\/01.ajg.0000798752.72296.f3","article-title":"P038 Ozanimod first-dose cardiac effects in patients with moderately to severely active ulcerative colitis and relapsing multiple sclerosis","volume":"116","author":"Long","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2024.03.010_bib0078","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2014.09.006","article-title":"Analysis of onset mechanisms of a sphingosine 1-phosphate receptor modulator fingolimod-induced atrioventricular conduction block and QT-interval prolongation","volume":"281","author":"Yagi","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dld.2024.03.010_bib0079","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ccep.2021.07.002","article-title":"Physiologic variants of cardiac conduction (aberration, gap, supernormal conduction)","volume":"13","author":"Miles","year":"2021","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.dld.2024.03.010_bib0080","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0081","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0082","doi-asserted-by":"crossref","first-page":"i094","DOI":"10.1093\/ecco-jcc\/jjab232.084","article-title":"DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis","volume":"16","author":"Armuzzi","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0083","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, Phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0084","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.03.010_bib0085","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","author":"Sandborn","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.dld.2024.03.010_bib0087","doi-asserted-by":"crossref","first-page":"i604","DOI":"10.1093\/ecco-jcc\/jjac190.0606","article-title":"P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme","volume":"17","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101515","article-title":"Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod","volume":"38","author":"Feige","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.dld.2024.03.010_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: insights from a pooled analysis of 15 randomised controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.dld.2024.03.010_bib0090","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1111\/jcmm.15744","article-title":"The role of sphingosine 1-phosphate and its receptors in cardiovascular diseases","volume":"24","author":"Ouyang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0091","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1476-5381.2012.01865.x","article-title":"FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase","volume":"166","author":"Spijkers","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dld.2024.03.010_bib0092","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/HYPERTENSIONAHA.117.09088","article-title":"S1PR1 (sphingosine-1-phosphate receptor 1) signaling regulates blood flow and pressure","volume":"70","author":"Cantalupo","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.dld.2024.03.010_bib0093","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/bph.14381","article-title":"The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension","volume":"176","author":"Don-Doncow","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dld.2024.03.010_bib0094","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/DDDT.S240861","article-title":"An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis","volume":"15","author":"Fronza","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.dld.2024.03.010_bib0095","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1093\/ibd\/izac032","article-title":"Hypertensive emergency after initiating ozanimod: a case report","volume":"28","author":"Choi","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0096","article-title":"Ozanimod in the treatment of ulcerative colitis: initial real-world data from a large tertiary center","author":"Cohen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0097","article-title":"Increasing incidence of inflammatory bowel disease with greatest change among the elderly: a nationwide study in Finland, 2000-2020","author":"Kontola","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0098","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3748\/wjg.v17.i22.2723","article-title":"Comorbidity in inflammatory bowel disease Comorbodity, the Context, definition","volume":"17","author":"L\u00f3pez San Rom\u00e1n","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2024.03.010_bib0099","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: a call for action","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.005892","article-title":"Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies","volume":"6","author":"Feng","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.dld.2024.03.010_bib0102","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cgh.2019.07.052","article-title":"Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study","volume":"18","author":"Jess","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0103","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030343","article-title":"Increased risk of diabetes in inflammatory bowel disease patients: a nationwide population-based study in korea","volume":"8","author":"Kang","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0104","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0106","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.21187","article-title":"Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study","volume":"16","author":"Andersohn","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0107","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.03.010_bib0108","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7196\/SAMJ.7979","article-title":"The influence of glucocorticoids on lipid and lipoprotein metabolism and atherosclerosis","volume":"104","author":"Ross","year":"2014","journal-title":"S Afr Med J"},{"key":"10.1016\/j.dld.2024.03.010_bib0109","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dld.2024.03.010_bib0110","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"Hageman","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dld.2024.03.010_bib0111","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2024.03.010_bib0112","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/bmj.p1028","article-title":"Cardiovascular disease risk assessment and reduction: summary of updated NICE guidance","volume":"381","author":"Samarasekera","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2024.03.010_bib0113","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"Kaptoge","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.dld.2024.03.010_bib0114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41575-022-00722-7","article-title":"Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance","volume":"20","author":"Danese","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0115","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2024.03.010_bib0116","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.3390\/jcm9103087","article-title":"Comprehensive lifestyle-modification in patients with ulcerative colitis\u2013a randomized controlled trial","volume":"9","author":"Langhorst","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0117","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"360","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.dld.2024.03.010_bib0118","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0119","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.03.010_bib0120","article-title":"Lipid changes after induction therapy in patients with inflammatory bowel disease: effect of different drug classes and inflammation","author":"Sleutjes","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.03.010_bib0121","unstructured":"Bristol Myers Squibb. ZEPOSIA\u00ae (ozanimod). Highlights of Prescribing Information. n.d."},{"key":"10.1016\/j.dld.2024.03.010_bib0122","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the american heart association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2024.03.010_bib0123","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0124","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/01.CIR.100.8.886","article-title":"ACC\/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations","volume":"100","author":"Crawford","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2024.03.010_bib0125","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.hrthm.2017.03.038","article-title":"2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring\/telemetry","volume":"14","author":"Steinberg","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.dld.2024.03.010_bib0126","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.dld.2024.03.010_bib0127","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a scientific statement from the american heart association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.dld.2024.03.010_bib0128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making\u2013pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.03.010_bib0129","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s12325-017-0545-4","article-title":"Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers","volume":"34","author":"Kariburyo","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.dld.2024.03.010_bib0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/apt.17286","article-title":"Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial","volume":"57","author":"Zisman-Ilani","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824003128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824003128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T07:29:31Z","timestamp":1722065371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824003128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":130,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1590865824003128"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.03.010","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}